When comparing survival outcomes based on TP53 mutation status within each subtype using the Kaplan-Meier estimated model, there were no differences in RFS or OS in HR+/HER2- (Figure 7A,B) and HER2-positive breast cancer (Figure 7C,D). This evidence concerns the gene TP53 and breast carcinoma.